<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LOSARTAN POTASSIUM <img border="0" src="../images/pr.gif"/></span><br/>(lo-sar'tan)<br/><span class="topboxtradename">Cozaar<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin ii receptor antagonist</span>; <span class="classification">antihypertensive</span><br/><b>Pregnancy Category: </b>C (first trimester); D (second and third trimesters)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg tablet</p>
<h1><a name="action">Actions</a></h1>
<p>Angiotensin II receptor (type AT<sub>1</sub>) antagonist acts as a potent vasoconstrictor and primary vasoactive hormone of the reninangiotensinaldosterone
         system.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Selectively blocks the binding of angiotensin II to the AT<sub>1</sub> receptors found in many tissues (e.g., vascular smooth muscle, adrenal glands). Antihypertensive effect results from blocking
         the vasoconstricting and aldosterone-secreting effects of angiotensin II.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to losartan, pregnancy [category C (first trimester), category D (second and third trimesters)], lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients on diuretics, renal or hepatic impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2550 mg in 12 divided doses (max: 100 mg/d); start with 25 mg/d if volume depleted (i.e., on diuretics)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>
            				Note: Starting dose is reduced 50% in patients with possible volume depletion or a history of liver disease.
            			
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, insomnia, headache. <span class="typehead"> GI:</span> Diarrhea, dyspepsia. <span class="typehead">Musculoskeletal:</span> Muscle cramps, myalgia, back or leg pain. <span class="typehead">Respiratory:</span> Nasal congestion, cough, upper respiratory infection, sinusitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Phenobarbital</b> decreases serum levels of losartan and its metabolite. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; approximately 2533% reaches systemic circulation. <span class="typehead"> Peak:</span>  6 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Highly bound to plasma proteins; does not appear to cross bloodbrain barrier. <span class="typehead">Metabolism:</span> Extensively metabolized in liver by cytochrome P450 enzymes to an active metabolite. <span class="typehead">Elimination:</span> 35% excreted in urine, 60% in feces. <span class="typehead">Half-Life:</span> Losartan 1.52 h; metabolite 69 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP at drug trough (prior to a scheduled dose).</li>
<li>Monitor drug effectiveness, especially in African-Americans when losartan is used as monotherapy.</li>
<li>Inadequate response may be improved by splitting the daily dose into twice-daily dose.</li>
<li>Lab tests: Monitor CBC, electrolytes, liver &amp; kidney function with long-term therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of symptoms of hypotension (e.g., dizziness, fainting).</li>
<li>Notify physician immediately of pregnancy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>